Bayer Healthcare South Africa Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes in the company’s development, and to what extent does Bayer’s recent development reflect the market changes? The first change has…
Abbott South Africa Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of Abbott South Africa? I worked in Abbott’s Pharmaceutical Division for 12 years, and then spent 3 years as General Manager…
Aspen The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting the best from the Mexican market – specifically with the acquisition of the Latin America business from India-based Strides Arcolab…
Astellas Czech Republic Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura, your colleague at Astellas Poland, has told Focus Reports that in Poland, Astellas’ first year was a nightmare. “It is safe to say,” he remarked, that…
Bomi de Mexico You took over BOMI as President and CEO only last year. Could you give us a brief background on BOMI Mexico and yourself? BOMI Mexico was founded in 1995. The mother company is Italian – and the Italian founder saw the potential in Latin America before most other pharmaceutical logistics…
Stallergenes Czech Republic Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did you decide to move down the value chain to a smaller, considerably more specialized biopharmaceutical company like Stallergenes, and what…
Serbian Chamber of Commerce Rather than Mr. Bugarin’s personal views, the following information contains general statements provided by the Serbian Chamber of Commerce Current trends in pharmaceutical industry The production of the medicines in all countries all around the world is one of the most important economic branches, not only as the economic activity,…
Ministry of Health (Republic of Serbia) Priorities and plans of the Ministry of Health If we entered an election year with a major reform plan, we would not succeed in putting such proposals into parliamentary procedure. Therefore, our aim is to adhere to the Action Plan of the Ministry of Health for 2011 which has been…
Commerce and Business Environment of Romania Within a broad assessment of Romania’s investment climate, there is no doubt that every country has some key factors upon which can be capitalized to attract foreign investors. In sum, how would you describe the current investment climate in Romania, and what are these factors that the country can leverage…
Dr. Reddy's Laboratories Romania You have been the first employee to start Dr. Reddy’s in Romania and when we look back at those early years, we see that a portfolio of gastroenterology and analgesics was chosen to enter the market… Why, in the first place, were these therapeutic areas targeted? At that time, the…
Fabiol Apart from MNCs, there are many local businesses that are rather strong in the Romanian pharmaceutical market. Could you give our readers an idea of their main strengths? There is great potential to source raw materials from within Romania. Romanian manufacturers that can easily work with these materials are not…
See our Cookie Privacy Policy Here
